Cervical Cancer

Overview
Epidemiology
The Role of HPV
Pathophysiology: CIN to Invasion
Risk Factors
Clinical Presentation
Screening and Diagnosis
FIGO Staging
Treatment
Prognosis
Research Papers
Connections
Featured Videos

1. Overview

Cervical cancer is cancer of the cervix — the narrow, lower portion of the uterus that opens into the vagina. It is the fourth most common cancer in women worldwide, yet it holds a remarkable and hopeful distinction among all cancers: it is one of the most preventable. Two powerful tools — the HPV vaccine and routine cervical screening (Pap smear) — have already slashed death rates dramatically in wealthy countries that have deployed them widely, and the same tools are now within reach of the rest of the world.

Virtually all cervical cancers (more than 99%) are caused by persistent infection with high-risk strains of human papillomavirus (HPV), a common sexually transmitted virus. This single well-established cause is what makes the disease so uniquely preventable: vaccinating against HPV before first exposure, and then screening for pre-cancerous changes before they turn invasive, can interrupt the process long before cancer ever forms.

Despite these tools existing for decades, cervical cancer still kills roughly 350,000 women every year globally, almost entirely because those women lacked access to vaccines or screening. The disease has become a profound example of a global health equity problem: the technology to prevent nearly every cervical cancer death exists, yet it remains unavailable to the women who bear the heaviest burden.

The World Health Organization's 90-70-90 strategy, launched in 2020, targets elimination of cervical cancer as a public health problem within a generation: 90% of girls vaccinated against HPV by age 15; 70% of women screened with a high-performance test by ages 35 and 45; 90% of women identified with cervical disease receiving treatment. Achieving these three targets in every country by 2030 would prevent an estimated 74 million cervical cancer cases and 62 million deaths by the end of this century.

In high-income countries such as the United States, the Pap smear — introduced in the 1940s — drove an approximately 70% decline in cervical cancer mortality over 50 years. The story of cervical cancer today is therefore two parallel stories: one of extraordinary public health success, and one of persistent, preventable suffering in the world's most vulnerable communities.

2. Epidemiology

In 2022, the Global Cancer Observatory (GLOBOCAN) estimated 660,000 new cases of cervical cancer and 350,000 deaths worldwide, making it the fourth most common cancer in women by incidence and mortality. It ranks second or third in many low-income nations, where it is frequently the leading cause of cancer death in women of reproductive age.

The global burden is strikingly unequal. Approximately 85% of new cases and 90% of deaths occur in low- and middle-income countries (LMICs), particularly in sub-Saharan Africa, South-East Asia, and Latin America. Countries such as Eswatini, Zambia, Zimbabwe, Malawi, and Tanzania have age-standardized incidence rates exceeding 50 per 100,000 women per year — more than ten times the rate in the United States or Western Europe. The disparity is almost entirely explained by differences in vaccine coverage and screening access, not by biology.

In the United States, about 13,820 new cases and 4,360 deaths are estimated for 2024 (American Cancer Society). The age-standardized incidence is approximately 7.5 per 100,000 women. The median age at diagnosis is around 50 years, with a bimodal distribution showing a first peak in the late 30s to 40s (invasive squamous cell carcinoma) and a smaller secondary peak in the 60s (adenocarcinoma).

Racial and ethnic disparities persist within the United States. Black women have a higher incidence rate (approximately 8.4 per 100,000) and a substantially higher mortality rate (approximately 3.8 per 100,000) compared with white women (incidence ~7.1, mortality ~2.2). Hispanic women also have higher incidence rates. These disparities reflect differences in HPV vaccination rates, access to screening, follow-up of abnormal results, and access to timely treatment — not biological differences in cancer susceptibility. Studies that control for socioeconomic status and insurance coverage largely eliminate the racial gap, underscoring that these are health system failures rather than inevitable outcomes.

Age-specific incidence drops sharply after age 65, which is why the American Cancer Society and USPSTF recommend stopping screening at 65 in women who have had adequate prior screening with normal results. New diagnoses in women over 65 are often in those who were never screened or under-screened. Young women under 25 have extremely low rates of invasive cancer, which is why guidelines do not recommend Pap smears before age 21 regardless of sexual activity.

3. The Role of HPV

Human papillomavirus (HPV) is a necessary cause of virtually all cervical cancers — the landmark 1999 meta-analysis by Walboomers and colleagues detected HPV DNA in 99.7% of invasive cervical cancer specimens from 22 countries. Understanding HPV biology is essential to understanding why cervical cancer develops, who is at risk, and why prevention works.

What HPV is. HPV is a small, non-enveloped, double-stranded DNA virus in the Papillomaviridae family. More than 200 genotypes (strains) exist. They are classified by their cancer-causing potential:

Low-risk types (e.g., HPV 6 and 11): cause genital warts (condylomata acuminata) and recurrent respiratory papillomatosis; rarely cause cancer.
High-risk (oncogenic) types: the International Agency for Research on Cancer (IARC) classifies 13 types as Group 1 carcinogens: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. HPV 16 and 18 alone account for approximately 70% of all cervical cancers. HPV 16 is primarily responsible for squamous cell carcinoma; HPV 18 for adenocarcinoma.

How HPV causes cancer: the molecular mechanism. HPV infects the basal keratinocytes of the squamous epithelium, typically at the squamocolumnar junction. In most productive infections, the viral genome remains as an extrachromosomal episome and the infection clears. In the minority of infections that persist and progress, the viral genome integrates into the host chromosome, disrupting the E2 gene. This integration is a critical step: E2 normally suppresses the viral oncoproteins E6 and E7, so its loss unleashes them.

E6 oncoprotein binds to the tumor suppressor p53 and targets it for proteasomal degradation. Without p53, cells cannot arrest at DNA-damage checkpoints or undergo apoptosis when their genome is damaged — mutations accumulate unchecked.
E7 oncoprotein binds to and inactivates the retinoblastoma protein (pRb), releasing E2F transcription factors that drive the cell into uncontrolled proliferation. E7 also triggers centrosome duplication errors, leading to chromosomal instability.

Together, E6 and E7 create a cell that cannot stop dividing, cannot repair its DNA, and accumulates the genomic chaos that defines cancer. The process from initial infection to invasive cancer typically takes 10 to 20 years — the long window that makes screening so effective.

Natural history. Most HPV infections are cleared by the immune system within 1 to 2 years. Approximately 90% of HPV infections clear without causing any lasting harm. Persistent infection — defined as the same high-risk type detected on two tests 12 months apart — is the key risk factor for cervical pre-cancer and cancer. Persistent HR-HPV infection is necessary but not sufficient: even among women with persistent infection, additional cofactors (smoking, immunosuppression, high parity) influence who progresses to cancer.

4. Pathophysiology: CIN to Invasion

Cervical cancer almost never arises in normal epithelium out of nowhere. It develops through a well-characterized sequence of precancerous changes called cervical intraepithelial neoplasia (CIN) — and it is this slow, step-by-step progression that makes early detection possible.

The transformation zone. The junction between the columnar epithelium of the endocervix and the squamous epithelium of the ectocervix is called the squamocolumnar junction (SCJ). The area around this junction, where squamous metaplasia normally occurs, is called the transformation zone (TZ). This is the critical target for HPV infection and the site where virtually all cervical cancers arise. Columnar cells undergoing metaplasia are especially vulnerable to HPV because of their proliferative activity.

The CIN spectrum. When high-risk HPV infects transformation zone cells and is not cleared, it can induce dysplastic changes graded by the depth of abnormal cells:

CIN 1 (mild dysplasia): Abnormal cells occupy the lower one-third of the epithelium. Often corresponds to active HPV infection. Regression rate approximately 60%; only about 1% progress to carcinoma in situ over 2 years. Management is usually watchful waiting with co-testing in 1 year.
CIN 2 (moderate dysplasia): Abnormal cells in the lower two-thirds. A biological intermediate — some are HPV-driven and will regress, others are genuine precancers. Regression rate approximately 40%; progression to CIN 3 or worse about 20%. Management is individualized (can observe in younger women hoping for regression, or treat).
CIN 3 / carcinoma in situ (severe dysplasia): Full-thickness or near-full-thickness dysplasia. Regression is uncommon (~33%); untreated, approximately 12% progress to invasive cancer within 5 years and up to 30% over 30 years. This is the lesion that must be treated.
Microinvasive carcinoma: Earliest invasive stage; cells breach the basement membrane but invasion is ≤5 mm deep. FIGO Stage IA.
Invasive carcinoma: Tumor penetrates beyond 5 mm or is clinically visible.

Histological types of invasive cervical cancer:

Squamous cell carcinoma (SCC): Approximately 70–75% of all invasive cervical cancers. Arises from the ectocervical squamous epithelium. Strongly associated with HPV 16. Has been declining in relative terms due to Pap smear success.
Adenocarcinoma: Approximately 20–25%, arising from the mucus-secreting glandular cells of the endocervical canal. More often associated with HPV 18. Has been rising as a proportion of cervical cancers, in part because adenocarcinoma is harder to detect by cytology (cells shed less reliably from the endocervix onto a Pap smear). Tends to occur at a slightly older age and may carry a slightly worse prognosis than SCC stage-for-stage in some studies.
Adenosquamous carcinoma: Mixed features; about 3–5% of cases.
Rare types: Small cell neuroendocrine carcinoma (very aggressive, rare, associated with HPV 18), clear cell carcinoma, glassy cell carcinoma, and others.

Patterns of spread. Invasive cervical cancer spreads by direct local extension into the parametrium (tissue lateral to the cervix), vagina, bladder, and rectum. Lymphatic spread is orderly: first to the paracervical and parametrial nodes, then to pelvic nodes (obturator, internal iliac, external iliac, common iliac), and then to para-aortic nodes. Hematogenous spread (to lungs, liver, bone, brain) is a late event. Parametrial involvement and lymph node metastasis are the most important adverse prognostic features.

5. Risk Factors

The essential risk factor for cervical cancer is persistent infection with a high-risk HPV type. All other risk factors act by either increasing the likelihood of acquiring high-risk HPV, impairing the immune system's ability to clear it, or promoting the progression from persistent infection to cancer.

Factors that increase HPV acquisition or persistence:

Multiple sexual partners and early age at first intercourse: increases cumulative HPV exposure. A woman with six or more lifetime sexual partners has approximately three times the risk of a woman with one partner, though HPV can be acquired from a single partner.
Male partner's sexual history: a woman's risk is partly determined by her partner's HPV status and number of prior partners.
Lack of HPV vaccination: the most important preventable risk factor.
Lack of or irregular screening: most invasive cervical cancers in the US are diagnosed in women who were never screened or under-screened.
Chlamydia trachomatis infection: associated with increased risk, possibly through cervical inflammation that facilitates HPV persistence.
High parity (≥3 full-term pregnancies): associated with approximately 3-fold increased risk, possibly because of hormonal effects that make the transformation zone more vulnerable or because pregnancy-related immune tolerance impairs HPV clearance.

Factors that impair HPV clearance or accelerate carcinogenesis:

Cigarette smoking: smokers have approximately twice the risk of SCC of the cervix compared with non-smokers. Smoking impairs local cervical immune surveillance and introduces tobacco carcinogens (including benzo[a]pyrene) directly into cervical mucus, which can compound the mutagenic effects of HPV.
HIV infection and other immunosuppressive conditions: HIV-positive women have a 5–10 fold higher risk of CIN and cervical cancer, with earlier onset and faster progression. Transplant recipients on immunosuppression, women on long-term systemic corticosteroids, and those with other immune deficiencies are also at elevated risk. Cervical cancer is an AIDS-defining illness.
Long-term oral contraceptive use (≥5 years): associated with approximately 2-fold increased relative risk of cervical cancer in HPV-positive women. The association appears to reverse after stopping OC use. The mechanism may involve hormonal upregulation of HPV gene expression.
Low socioeconomic status: a proxy for reduced access to screening and vaccination, and for higher rates of HPV-related cofactors. Poverty is the most powerful predictor of cervical cancer death worldwide.
Diethylstilbestrol (DES) exposure in utero: daughters of women who took DES during pregnancy have an elevated risk of clear cell adenocarcinoma of the cervix and vagina (rare but important historical cause).

6. Clinical Presentation

One of the most important things to understand about cervical cancer is that early-stage disease is almost always silent. CIN and Stage I invasive cancer typically produce no symptoms at all — which is precisely why screening exists. By the time symptoms appear, the cancer has usually progressed to a more advanced stage.

Early warning signs (when present):

Abnormal vaginal bleeding is the most common symptom of early invasive cervical cancer. This includes:
- Postcoital bleeding (bleeding after intercourse) — a particularly important warning sign that should never be dismissed as "normal."
- Intermenstrual bleeding (bleeding between periods).
- Postmenopausal bleeding in a woman who has not had a period for 12 months.
- Heavier or longer menstrual periods than usual.
Unusual vaginal discharge: watery, blood-tinged, or foul-smelling discharge that differs from a woman's usual pattern. The odor may result from tumor necrosis.
Pelvic discomfort or pain: a dull, persistent ache in the lower pelvis or lower back, distinct from typical menstrual cramping.

These symptoms are common and usually caused by something far less serious than cancer (infections, benign polyps, hormone changes). However, any woman with these symptoms — particularly postcoital bleeding — should be evaluated promptly. Studies consistently show that delays in diagnosis occur most often because either the woman dismissed the symptom or because the healthcare provider did not take it seriously enough.

Advanced disease symptoms reflect local extension and distant spread:

Hydronephrosis and renal failure: the ureters run close to the lateral cervix; parametrial tumor growth can compress or obstruct them, causing hydroureter and hydronephrosis. Bilateral ureteral obstruction leads to renal failure and is a leading cause of death from locally advanced cervical cancer.
Leg edema: lymphatic obstruction from nodal metastases or direct vascular compression causes one or both legs to swell.
Fistulas: tumor invasion into the bladder or rectum can create abnormal connections — vesicovaginal fistula (urine leaking through the vagina) or rectovaginal fistula (fecal material passing through the vagina). These are deeply distressing complications that significantly affect quality of life.
Hematuria and rectal bleeding: from direct invasion of bladder or rectal mucosa (Stage IVA).
Back and flank pain: from para-aortic lymphadenopathy or ureteral obstruction.
Sciatic pain and leg weakness: from pelvic sidewall involvement compressing the sciatic nerve.
Systemic symptoms: unexplained weight loss, fatigue, loss of appetite — signs of advanced malignancy.

7. Screening and Diagnosis

Cervical cancer screening is one of medicine's great success stories. The Pap smear, introduced in clinical practice in the 1940s based on the work of Georgios Papanicolaou, reduced U.S. cervical cancer mortality by approximately 70% over five decades. Adding HPV testing to cytology has made screening even more sensitive.

Current U.S. screening guidelines (ASCCP 2019 / USPSTF 2018):

Ages 21–29: Pap smear (cytology) alone every 3 years. HPV testing is not recommended for this age group because transient HPV infections are common and co-testing would generate excessive false positives leading to unnecessary procedures.
Ages 30–65: Primary HPV test alone every 5 years (preferred) using an FDA-approved high-risk HPV assay; OR HPV co-test (HPV + cytology) every 5 years; OR cytology alone every 3 years (acceptable).
Ages 65+: Stop screening if the woman has had adequate prior screening (defined as 3 consecutive negative cytology tests or 2 consecutive negative HPV or co-tests in the past 10 years, the most recent within 5 years) and no history of CIN 2 or worse in the last 25 years. Women who were never screened should continue to be screened into their 70s.
After hysterectomy with cervix removed: No further screening needed if no history of CIN 2 or worse.

Managing abnormal results — the ASCCP risk-based framework:

The 2019 ASCCP guidelines shifted from a result-based to a risk-based approach. The immediate action depends not just on the current test result, but on accumulated risk over time (incorporating prior results, prior treatments, and patient age). The key pathways include:

ASC-US (atypical squamous cells of undetermined significance) + negative HPV: very low risk; return to routine screening in 3 years.
ASC-US + positive HPV (or HPV positive alone): refer to colposcopy if HPV 16/18 positive; 1-year co-test if other high-risk HPV types.
LSIL (low-grade squamous intraepithelial lesion): age-dependent; in women 25 and older, colposcopy is typically recommended.
ASC-H (cannot exclude HSIL) or HSIL (high-grade SIL): immediate colposcopy.
Colposcopy: visual examination of the cervix under magnification with acetic acid (which turns abnormal cells white). Directed biopsies are taken from abnormal areas. Endocervical curettage (ECC) is performed to sample the endocervical canal.
CIN 2–3 / HSIL confirmed on biopsy: treatment by LEEP (loop electrosurgical excision procedure) — using a thin wire loop and electrical current to excise the transformation zone — or cold-knife cone biopsy. Excision is both diagnostic (provides tissue for histology, confirms complete removal by negative margins) and therapeutic.

Diagnostic workup when cancer is suspected:

Examination under anesthesia (EUA) with colposcopy, directed biopsies, and ECC for staging of visible lesions.
MRI pelvis and abdomen: the preferred imaging modality for local staging; defines tumor size, parametrial invasion, vaginal extension, and lymph node involvement. Has replaced CT for local staging in most centers.
CT chest/abdomen/pelvis: for assessing distant metastases and para-aortic nodal disease.
PET-CT: increasingly used pre-treatment for locally advanced disease to detect occult nodal and distant metastases that would alter treatment planning; also used in post-treatment surveillance.
Cystoscopy and proctoscopy: if bladder or rectal involvement is suspected (Stage IVA).
Renal function and urinalysis: essential; hydronephrosis upstages disease to Stage IIIB and is also a clinical emergency requiring ureteral stenting.

HPV vaccines and primary prevention. The 9-valent Gardasil-9 vaccine (Merck) targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 — covering the low-risk types that cause genital warts, and the five additional high-risk types beyond 16 and 18 that together account for an additional ~15% of cervical cancers. In clinical trials, the 9-valent vaccine showed nearly 100% efficacy against CIN 2/3 and cervical cancer caused by the covered types. ACIP recommends routine vaccination at age 11–12 (can start at 9); 2-dose series if started before age 15; 3-dose series at ages 15 through 45. Shared clinical decision-making for ages 27–45; benefit is lower because many adults have already been exposed to HPV. Vaccination is also recommended for males and for individuals who are immunocompromised.

8. FIGO Staging (2018)

Cervical cancer is staged using the system of the International Federation of Gynecology and Obstetrics (FIGO). A major update in 2018 revised the staging to incorporate imaging and pathological findings — not just clinical examination as in prior editions — including lymph node involvement, which is now formally included in Stage III. This change acknowledged the global reality that imaging is now widely available and that nodal status profoundly affects prognosis.

FIGO 2018 Staging Summary:

Stage I — Confined to the cervix uteri
- IA: Microscopic invasive carcinoma only (diagnosed by microscopy)
  - IA1: Stromal invasion ≤3 mm in depth
  - IA2: Stromal invasion >3 mm and ≤5 mm
- IB: Clinically visible lesion or lesion with microscopic invasion >5 mm
  - IB1: Tumor >5 mm invasion depth, <2 cm in greatest dimension
  - IB2: Tumor ≥2 cm and <4 cm
  - IB3: Tumor ≥4 cm
Stage II — Beyond the uterus, but not to the lower third of vagina or pelvic sidewall
- IIA: Upper two-thirds of vagina, no parametrial involvement
  - IIA1: <4 cm; IIA2: ≥4 cm
- IIB: Parametrial involvement (but not to the pelvic sidewall)
Stage III — Extends to lower vagina and/or pelvic sidewall, hydronephrosis, or lymph node involvement
- IIIA: Involvement of lower third of vagina
- IIIB: Pelvic sidewall involvement and/or hydronephrosis or non-functioning kidney
- IIIC: Pelvic or para-aortic lymph node involvement (r = imaging; p = pathological)
  - IIIC1: Pelvic lymph node metastasis
  - IIIC2: Para-aortic lymph node metastasis
Stage IVA: Invasion of bladder or rectal mucosa
Stage IVB: Distant metastases (including inguinal lymph nodes and intraperitoneal disease)

A key clinical point: parametrial involvement (Stage IIB) is the pivotal staging threshold that typically shifts treatment from surgery to concurrent chemoradiation. Determining whether parametrial fat is involved by tumor is one of the most important decisions in cervical cancer staging, and MRI is substantially more accurate than clinical examination for this determination.

9. Treatment

The treatment of cervical cancer is highly stage-dependent and requires a multidisciplinary team including gynecologic oncologists, radiation oncologists, and medical oncologists. For early-stage disease, surgery and radiation are equally effective; for locally advanced disease, definitive concurrent chemoradiation is the standard of care.

Pre-invasive disease (CIN 2–3)

LEEP or cold-knife cone biopsy is both curative and diagnostic. A LEEP can be performed in an office setting under local anesthesia. Cold-knife cone (CKC) is preferred when endocervical canal disease extends beyond the reach of LEEP or when glandular lesions (adenocarcinoma in situ, AIS) are present, as it provides better assessment of endocervical margins. Recurrence after adequate excision with negative margins is low (~5%), but follow-up with co-testing at 6 months, 12 months, and 3 years is mandatory.

Stage IA1 (no lymphovascular space invasion)

Conization (cone biopsy) with negative margins is adequate for women who wish to preserve fertility. Simple extrafascial hysterectomy is appropriate for women who have completed childbearing. The risk of lymph node metastasis is <1% and pelvic lymph node dissection is not required.

Stage IA1 with LVSI and Stage IA2

Modified radical hysterectomy (Type II) with bilateral pelvic lymph node dissection is the standard surgical approach, or sentinel lymph node biopsy in select centers. Alternatively, concurrent chemoradiation is appropriate for patients who are not surgical candidates.

Stage IB1–IIA1 (tumor <4 cm)

Both radical hysterectomy (Type III / Wertheim-Meigs) with bilateral pelvic lymph node dissection and definitive concurrent chemoradiation achieve equivalent survival outcomes in multiple randomized trials and meta-analyses. Treatment choice is individualized:

Surgery is often preferred in younger women because it avoids radiation to the ovaries (allowing ovarian function preservation), avoids late radiation effects on the vagina and bladder, provides definitive pathologic staging, and allows post-surgical adjuvant decisions based on pathology. Sentinel lymph node mapping is an increasingly accepted alternative to full lymphadenectomy in tumors ≤4 cm.
Radiotherapy avoids surgical morbidity and is preferred when surgical risk is high (obesity, medical comorbidities) or patient preference dictates.
The GOG-92 trial (Peters et al., 2000) established that women with adverse pathological features after radical hysterectomy (positive margins, positive nodes, or parametrial involvement) benefit from adjuvant concurrent cisplatin-based chemoradiation. Sedlis criteria (LVSI, deep stromal invasion, large tumor size) define intermediate-risk women who also benefit from adjuvant radiation.

Stage IB2–IIA2 (tumor ≥4 cm) and Stages IIB–IVA: Definitive Concurrent Chemoradiation

This is the cornerstone of treatment for locally advanced cervical cancer and one of the best-validated treatment regimens in gynecologic oncology. Five landmark randomized trials published in 1999–2000 (GOG protocols 85, 109, 120, 123, and RTOG 90-01) all demonstrated superior survival for cisplatin-containing concurrent chemoradiation over radiation alone, reducing the risk of death by 30–50%. This evidence cemented the regimen as standard of care.

The regimen:

External beam radiation therapy (EBRT): 45–50 Gy to the whole pelvis (with parametria and regional lymph nodes) over 5 weeks, using intensity-modulated radiation therapy (IMRT) to spare the bladder, rectum, and bowel.
Concurrent cisplatin: 40 mg/m² IV weekly during EBRT. Acts as a radiosensitizer. Carboplatin or 5-fluorouracil can substitute for cisplatin-intolerant patients.
Intracavitary brachytherapy (ICBT): a radiation source placed inside the cervix/uterus to deliver a high dose boost directly to the primary tumor. This is not optional — it is essential. Studies consistently show that omitting brachytherapy and substituting external beam boost severely compromises local control and survival. MRI-guided adaptive brachytherapy (the GEC-ESTRO approach) optimizes target coverage while minimizing bladder and rectal doses.

Para-aortic lymph node involvement (Stage IIIC2) is addressed by extending the radiation field to cover para-aortic nodes — the "extended field" approach — though this increases toxicity (nausea, diarrhea, bone marrow suppression).

Recurrent and Metastatic Cervical Cancer: Systemic Therapy

Until recently, options for recurrent or metastatic cervical cancer were limited and outcomes poor. The past decade has seen transformative advances:

Cisplatin-based doublet chemotherapy + bevacizumab: The GOG-0240 trial (Coleman et al., 2014, Lancet) established that adding bevacizumab (an anti-VEGF antibody) to cisplatin/paclitaxel improved overall survival from 13.3 months to 17.0 months (HR 0.71) in recurrent/metastatic cervical cancer — the first time any agent beyond chemotherapy had improved OS in this setting. This regimen became standard first-line therapy for recurrent/metastatic disease.
Pembrolizumab (anti-PD-1 checkpoint inhibitor) + chemotherapy ± bevacizumab: The KEYNOTE-826 trial (Monk et al., NEJM 2021) was practice-changing. Adding pembrolizumab to platinum-based chemotherapy ± bevacizumab significantly improved progression-free survival (10.4 vs. 8.2 months) and overall survival (24.4 vs. 16.3 months) in women with PD-L1 CPS ≥1, who constitute the majority of patients. The benefit was also seen in the overall population. Pembrolizumab + cisplatin/paclitaxel ± bevacizumab is now the preferred first-line regimen for persistent, recurrent, or metastatic cervical cancer.
Tisotumab vedotin (TV): an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein highly expressed on cervical cancer cells. TV delivers the potent microtubule-disrupting toxin monomethyl auristatin E (MMAE) directly to TF-expressing tumor cells. The innovaTV 204 trial (Elit et al., Lancet Oncol. 2021) showed a 24% overall response rate in heavily pretreated recurrent/metastatic cervical cancer — compelling in a population with very few options. TV was FDA-approved in 2021 for adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Fertility-Sparing Surgery: Radical Trachelectomy

For young women with Stage IB1 (≤2 cm, no nodal metastases) who strongly wish to preserve fertility, radical trachelectomy is an option. The surgeon removes the cervix, upper vagina, and parametria while preserving the uterine corpus. A cerclage is placed at the uterine isthmus. Pregnancy rates of 40–70% have been reported in selected series, with preterm birth the main obstetric complication. Oncologic outcomes are comparable to radical hysterectomy in carefully selected patients.

A note on prevention through vaccination. While treatment is effective, the greatest opportunity in cervical cancer lies upstream. The 9-valent HPV vaccine, when given to pre-adolescent girls and boys before HPV exposure, prevents the infections that cause virtually all cervical cancers. Countries with high vaccine coverage (Australia, UK, Scandinavia) are already seeing dramatic reductions in CIN and early invasive cervical cancer rates in vaccinated cohorts. Australia is on track to become the first country to eliminate cervical cancer as a public health problem, defined as incidence <4 per 100,000 women per year, within this decade.

10. Prognosis

Cervical cancer prognosis is strongly dependent on stage at diagnosis, with a dramatic gradient from near-complete curability in early stages to poor outcomes in metastatic disease. This stage-dependency is both the argument for screening (catch it early) and a measure of how much is lost when access to screening is absent.

Approximate 5-year relative survival rates by stage (SEER data, US):

Stage IA (microinvasive): approximately 93–98%
Stage IB: approximately 80–90%
Stage IIA: approximately 65–75%
Stage IIB: approximately 55–70%
Stage IIIA–IIIB: approximately 30–50%
Stage IIIC: approximately 25–40% (worse with para-aortic nodes)
Stage IVA: approximately 15–20%
Stage IVB (distant metastases): approximately 5–15%

Key prognostic factors:

Stage: the single most important factor.
Lymph node metastasis: positive pelvic nodes reduce 5-year survival by approximately 40–50% compared to node-negative disease at the same local stage. Para-aortic nodes confer the worst prognosis.
Parametrial involvement: the shift from IB to IIB marks a substantial decline in outcomes because parametrial disease usually precludes surgery and indicates more aggressive tumor biology.
Tumor size: within Stage IB, tumor ≥4 cm (IB3) has worse outcomes than smaller tumors.
Histology: squamous cell carcinoma and adenocarcinoma have broadly similar prognosis stage-for-stage, though adenocarcinoma may carry a modest survival disadvantage in some stage subgroups. Small cell neuroendocrine carcinoma is rare but highly aggressive with poor prognosis.
Response to chemoradiation: complete clinical and radiological response at 3 months post-treatment is strongly predictive of long-term disease control in locally advanced disease. PET-CT is the preferred tool for response assessment.
PD-L1 expression (CPS score): in the recurrent/metastatic setting, CPS ≥1 (present in ~90% of patients) predicts benefit from pembrolizumab. CPS ≥10 shows even greater benefit.
Performance status and nutritional state: patients presenting with bilateral hydronephrosis, fistulas, or poor functional status have substantially worse outcomes from any treatment.

For women who complete definitive treatment, surveillance includes pelvic exam and cytology every 3–6 months for 2 years, then every 6–12 months to year 5, then annually. Late recurrences beyond 5 years are uncommon but occur. Survivors face potential long-term effects of radiation: bowel, bladder, and sexual dysfunction — which require proactive management and referral to pelvic floor physical therapy, sexual health counseling, and gastroenterology as needed.

11. Research Papers

The following peer-reviewed publications have been especially influential in shaping our understanding and treatment of cervical cancer. Each citation links to its PubMed abstract.

Walboomers JM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19. PMID 10451482
Cohen PA et al. Cervical cancer. Lancet. 2019;393(10167):169–182. PMID 30638582
Rose PG et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–1153. PMID 10202165
Keys HM et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154–1161. PMID 10202166
Peters WA et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606–1613. PMID 10764420
Kjaer SK et al. A pooled analysis of continued prophylactic efficacy of quadrivalent HPV vaccine against high-grade cervical and external genital lesions. Cancer Prev Res. 2009;2(10):868–878. PMID 19789295
Massad LS et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S1–27. PMID 23519301
Coleman RL et al. Bevacizumab and combination chemotherapy in recurrent or metastatic cervical cancer: GOG-0240 randomised study. Lancet. 2014;385(9980):1829–1838. PMID 24505710
Bhatla N et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019;145(1):129–135. PMID 30656645
Perkins RB et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102–131. PMID 32243307
Monk BJ et al. Pembrolizumab plus chemotherapy versus chemotherapy in advanced cervical cancer (KEYNOTE-826). N Engl J Med. 2021;385(20):1856–1867. PMID 34534429
Elit L et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6). Lancet Oncol. 2021;22(5):609–619. PMID 33845034

PubMed topic searches for further reading:

Connections

Back to Table of Contents